small molecule

PREZISTA

DARUNAVIR

Loss of exclusivityJune 2027latest FDA-listed patent expiry
CompanyJANSSEN PRODUCTS LP

Drug detail

Brand namePREZISTA
Active ingredientDARUNAVIR
Strength300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2006
Marketing statusDISCN

Listed patents

PatentExpiresType
7700645*PEDJune 2027
7700645December 2026substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PREZISTA patent cliff — loss of exclusivity June 2027 | CliffBio